1
Patients with leukopenia should be considered as recipients of prophylaxis for relapse.
2
The major dose-limiting toxic effect for all three agents was leukopenia.
3
Cycle delays due to leukopenia were similar in both arms of the study.
4
High-dose uridine given as intermittent intravenous infusions was feasible and reversed 5-FU-induced leukopenia.
5
Lithium administration has been shown to attenuate the leukopenia associated with systemic chemotherapy.
6
The dose-limiting toxic effect was leukopenia which was dose-related and reversible.
7
Toxicities were acceptable and consisted primarily of leukopenia and gastrointestinal toxicity.
8
The cause of the peripheral leukopenia and thrombocytopenia is not known.
9
However, we could not confirm the association with late leukopenia in the Japanese subjects.
10
In all, one quarter of treatment courses were delayed, most frequently because of leukopenia.
11
Nucleated cell counts were taken after confirming onset of leukopenia.
12
Dose-related anemia and leukopenia were observed and were infrequently severe.
13
The dose-limiting toxicity of VP was moderate to severe leukopenia.
14
Laboratory examination revealed leukopenia and abnormal liver function on admission.
15
Adverse events including leukopenia were reviewed from medical records.
16
Peptidoglycan also causes a late leukopenia and thrombocytopenia which may occur independently of complement activation.
